Summary
Merck & Co., Inc. reported total sales of $44.03 billion for the fiscal year ended December 30, 2013. This represents a 7% decrease from the previous year, largely attributed to the loss of market exclusivity for key products like Singulair, coupled with ongoing global healthcare cost containment pressures. Despite the revenue decline, Merck demonstrated effective cost management, with marketing and administrative expenses and R&D costs decreasing by over $1.5 billion combined compared to 2012. The company also highlighted a significant restructuring program initiated in October 2013, aiming to reduce its workforce by approximately 8,500 positions and sharpen its commercial and R&D focus to drive future growth. Merck continued to return value to shareholders, repurchasing shares and paying dividends, signaling confidence in its long-term strategy and pipeline.
Financial Highlights
53 data points| Revenue | $44.03B |
| Cost of Revenue | $16.95B |
| Gross Profit | $27.08B |
| R&D Expenses | $7.50B |
| SG&A Expenses | $11.91B |
| Interest Expense | $801.00M |
| Net Income | $4.40B |
| EPS (Basic) | $1.49 |
| EPS (Diluted) | $1.47 |
| Shares Outstanding (Basic) | 2.96B |
| Shares Outstanding (Diluted) | 3.00B |
Key Highlights
- 1Total sales for 2013 were $44.03 billion, a 7% decrease from $47.27 billion in 2012, primarily due to patent expiries of major products like Singulair.
- 2Significant cost-saving measures were implemented, with combined Marketing & Administrative and R&D expenses decreasing by over $1.5 billion compared to 2012.
- 3Merck announced a major global restructuring program targeting approximately 8,500 job reductions to streamline operations and focus on key therapeutic areas: diabetes, acute hospital care, vaccines, and oncology.
- 4The company continued to prioritize shareholder returns, repurchasing $6.5 billion of its common stock and raising its quarterly dividend.
- 5Key products showing growth included Gardasil (vaccine), Remicade and Simponi (immunology), Janumet (diabetes), and Isentress (HIV).
- 6Merck is actively managing its product pipeline, with several candidates under regulatory review, including the nine-valent HPV vaccine (V503) and an anti-PD-1 immunotherapy (MK-3475) for advanced melanoma.
- 7The company is evaluating strategic options for its Animal Health and Consumer Care businesses to enhance long-term value creation.